培塞利珠单抗治疗大动脉炎
本文报告10例育龄女性难治性大动脉炎患者使用培塞利珠单抗(CZP)治疗,中位疗程10个月。所有患者迅速应答,9/10例印度大动脉炎临床活动评分2010恢复正常,中位血清CRP显著下降,全部达到缓解;7例维持缓解至少4个月,1例治疗2年后复发,5例出现轻度感染。作者认为CZP可能是活动性大动脉炎的有效且节约激素的治疗选择。
要点
- 10例育龄女性难治性大动脉炎患者接受培塞利珠单抗治疗,全部迅速应答并达到缓解。
- 9/10例印度大动脉炎临床活动评分2010恢复正常,中位血清CRP显著下降。
- 7例维持缓解至少4个月,1例治疗2年后复发,5例出现轻度感染。
核心结论
- 作者认为,培塞利珠单抗可能是活动性大动脉炎患者的有效且节约激素的治疗选择,即使这些患者既往对其他TNF抑制剂或托珠单抗无应答。
研究设计与样本
- 病例系列研究,纳入10例育龄女性(18-35岁)大动脉炎患者。
- 培塞利珠单抗给药方案为第0、2、4周400 mg,此后每2周200 mg,中位治疗10个月(范围3-28个月)。
- 所有患者在培塞利珠单抗治疗前均接受糖皮质激素和(或)甲氨蝶呤、环磷酰胺、硫唑嘌呤、羟氯喹、来氟米特或吗替麦考酚酯治疗;6例既往接受过其他生物抗细胞因子药物治疗。
- 采用美国国立卫生研究院标准与印度大动脉炎临床活动评分2010定义疾病活动性。
主要发现
- 所有患者对培塞利珠单抗治疗迅速应答,并能够逐渐减少泼尼松和甲氨蝶呤剂量。
- 培塞利珠单抗治疗使中位血清CRP水平显著下降,并使10例中9例的印度大动脉炎临床活动评分2010恢复正常。
- 全部患者达到系统性血管炎缓解;7例维持缓解至少4个月,1例在培塞利珠单抗治疗2年后出现复发。
- 副作用包括轻度感染(n=5)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Certolizumab pegol (CZP) is a PEGylated antigen-binding fragment-fragment of a humanized mAb neutralizing TNF. It lacks Fc-fragment and has a very low potential to cross the placenta. We aimed to report the efficacy and safety of CZP in a case series of patients with refractory Takayasu arteritis (TA). METHODS: Ten females of reproductive age (18-35 years) with TA were treated with CZP (at a dose of 400 mg at weeks 0, 2 and 4 and at 200 mg every 2 weeks thereafter) for a median of 10 months (range 3-28). Prior to CZP administration all patients received glucocorticoids and ± MTX, CYC, AZA, HCQ, LEF or MMF. Six patients were previously treated with other biological anti-cytokine drugs. The National Institutes of Health criteria and the Indian Takayasu Clinical Activity Score 2010 were used to define disease activity. RESULTS: All patients rapidly responded to treatment with CZP and were able to taper prednisone and MTX doses. Treatment with CZP resulted in a significant decrease in median serum CRP levels and normalization of Indian Takayasu Clinical Activity Score 2010 score in 9 of 10 patients. Remission of systemic vasculitis was achieved in all patients. Seven patients maintained remission for at least 4 months, while one patient developed relapse after 2 years of CZP treatment. Side effects included mild infections (n = 5). CONCLUSION: Our case series suggests that CZP may be an effective and steroid-sparing treatment option in patients with active TA even if they did not previously respond to other TNF inhibitors or tocilizumab.
引用
- Novikov PI, Smitienko IO, Sokolova MV, et al. Certolizumab pegol in the treatment of Takayasu arteritis. Rheumatology (Oxford). 2018. PMID: 30010945. doi:10.1093/rheumatology/key197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。